Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries

Dr Mohamed Ibrahim is a Professor of Social and Administrative Pharmacy at College of Pharmacy, Qatar University. He obtained his PhD degree in Pharmacy Administration from the Philadelphia College of Pharmacy & Science (PCPS), Philadelphia, USA in 1995. He was a founding Program Chairman for Social & Administrative Pharmacy Program. He also served as founding Chairman, Department of Pharmacy Practice, Al Qassim University, KSA and founding Assoc. Dean of Research & Graduate Studies Affairs, College of Pharmacy, Qatar University. He was formerly a Professor at School of Pharmaceutical Sciences, Universiti Sains Malaysia and College of Pharmacy, Qassim University, Al-Qassim, KSA. His areas of research, publication and consultancy are in the area of Social & Administrative Pharmacy that focus on Pharmaceutical Policy & Supply Management, Pharmacoeconomics, Pharmacoepidemiology, Socio-behavioral Aspects of Pharmacy, and Pharmaceutical Management & Marketing. Dr. Mohamed Ibrahim has supervised and/or participated in the training of over 70 MSc and PhD graduate students from 14 countries in Africa and Asia. He has published over 250 peer-reviewed papers, multiple proceedings, monographs, research reports and other publications, including authoring or editing 12 books and multiple book chapters.. He is a co-editor of Pharmacy Practice in Developing Countries: Achievements and Challenges (Elsevier, 2016). He is part of the editorial board member and reviewers in many peer review international journals. Dr. Mohamed Ibrahim has presented more than 100 invited presentations, and is the recipient of 9 international, 18 national and 11 university research grants, and is also the recipient of 2015 Scopus Medical & Health Science Scientist Award. He has functioned in multiple consultant roles to government in Malaysia, Sudan, Mongolia, Qatar, and non-governmental bodies at national and international levels (WHO, HAI). Albert I Wertheimer is a professor of pharmacy economics at Nova Southeastern University (NSU) in Fort Lauderdale, Florida, USA. Previously, he was a professor at Temple University, and at the University of Minnesota, and the Dean at the Philadelphia College of Pharmacy. He earned his pharmacy degree at the University of Buffalo, his MBA at the State University of New York at Buffalo, and his PhD from Purdue University. He was also a postdoctoral fellow in the Social Medicine Department of St. Thomas’ Hospital Medical School, University of London.He is the author or co-author of 35 books, many book chapters and about 430 articles in scientific and professional journals. He is the editor of the Journal of Pharmaceutical Health Services Research. He has advised 90 PhD graduates and more than that number of Masters degree students. In addition, he has been the advisor of about 15 postdoctoral research fellows. Dr. Wertheimer has lectured or consulted in about 70 countries. He received the research achievement award from the American Association of Pharmaceutical Scientists, is a fellow of the International Pharmacy Federation (FIP) and is a Scheele Laureat from the Swedish Academy of Pharmaceutical Sciences. He is peer reviewer for about 20 journals and on the editorial board of three. He holds adjunct appointments at Pharmacy faculties in Malta, China, Turkey, Taiwan. Slovenia, and Mexico. Currently, he is working in the area of health policy analysis. With over 25 years of experience in pharmaceutical policy and practice research, Prof Zaheer Babar is a global authority and a prolific author in this field. He comes with a long-standing academic career in pharmacy in New Zealand, and the United Kingdom. He is globally known for his work in policy and practice, including quality use of medicines, and issues related to medicines access and pricing. Prof. Babar has published over 300 papers and is considered the leading researcher in the “pharmacy practice research category”. He has published in high-impact journals such as PLoS Medicine and the Lancet and has acted as a consultant for the WHO, RPS, UNDP, HAI, MSH, FIP, International Union Against Tuberculosis and Lung Disease, World Bank, European Union, and the Pharmaceutical Management Agency of New Zealand. His edited work includes "Economic Evaluation of Pharmacy Services", "Pharmaceutical Prices in the 21st Century", "Pharmaceutical Policies in Countries with Developing Healthcare Systems", "Global Pharmaceutical Policy", "Access to high-cost medicines", "Pharmacy Practice Research Methods", "Pharmacy Practice Research Case Studies" , "Encyclopaedia of Pharmacy Practice and Clinical Pharmacy", and "Encyclopaedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy". Published by Elsevier and Adis/Springer, his work is used in curriculum design, policy development, and referral all around the globe. Professor Babar is the founding Editor-In-Chief of the Journal of Pharmaceutical Policy and Practice [IF = 4.2], a high-impact publication that provides evidence-based insights and recommendations for policymakers, practitioners, and researchers. He can be contacted at: z.babar@hud.ac.uk

1. Introduction: Discovering Issues and Challenges in Low- and Middle-Income Countries Section I: Socio-behavioral Aspects of Medicines Used in Low- and Middle-Income Countries 2. Socio-Behavioral Aspects of Medicine Used in Low- and Middle-Income Countries 3. Patients’, Consumers’ and Healthcare Professionals’ Perceptions, Beliefs, Knowledge, Attitudes and Practices Towards the Use of Medicines 4. The Use of Measurements and Health Behavioral Models to Improve Medication Adherence

Section II: Pharmaceutical Promotion in Low- and Middle-Income Countries 5. Academic Detailing in Low- and Middle-Income Countries: Principles, Use, Impact and Lessons Learned Section III: Economic Evaluation and Medicine Expenditure in Low- and Middle-Income Countries 6. Economic Evaluation and Medicine Expenditure in Low- and Middle-Income Countries 7. Medicine Pricing Policy and Strategies in Low- and Middle-Income Countries: A Review 8. Economic Evaluation of Predominant Disease in Low- and Middle-Income Countries: Diabetes Mellitus Section IV: Pharmacovigilance and Patient Safety in Low- and Middle-Income Countries 9. Pharmacovigilance Practices and Activities: Issues, Challenges, and Future Direction 10. Behavioral Aspects of Pharmacovigilance: Research Methods Considerations 11. Knowledge, Attitude, and Practice of Pharmacovigilance in Low- and Middle-Income Countries Section V: Generic Medicines Used in Low- and Middle-Income Countries 12. Overcoming Challenges of Generic Medicine Utilization in Low- and Middle-Income Countries: Lessons Learned from International Experiences 13. Assessment of Policies, Determinants and Characteristics of Generic Medicine Entry into the Pharmaceutical Markets Section VI: Rational and Responsible Medicine Use in Low- and Middle-Income Countries 14. Misconceptions and Misues of Drugs by Prescribers, Dispensers and Consumers 15. Strengths and Weaknesses of Pharmaceutical Policy in Relation to Rational and Responsible Medicines Use 16. Rational and Responsible Medicines Use Section VII: Quality of Public Health Pharmacy Services in Low- and Middle-Income Countries 17. Quality of Pharmacy Health Services 18. Assessment of Medicine Dispensing and Extended Community Pharmacy Services 19. Enhancing Quality of Patient-Centered Care Services in Low- and Middle-Income Countries: Pharmaceutical Care Approach 20. Politics and Competition between Professions: Future Scope of Pharmacy Practice Section VIII: Medicine Quality: Substandard and Counterfeit Medicine in Low- and Middle-Income Countries 21. Perspective, Knowledge, Attitude, and Belief of Various Stakeholders on Medicines Quality: Counterfeit and Substandard Medicines Section IX: Medicine Information and Health Literacy in Low- and Middle-Income Countries 22. Issues on Source, Access, Extent and Quality of Information Available Among Pharmacists and Pharmacy Personnel to Practice Effectively Section X: Good Governance and Pharmaceutical Policy in Low- and Middle-Income Countries 23. Problems and Obstacles of Low- and Middle-Income Countries in Having Good Governance and Quality and Effective Pharmaceutical Policy 24. Pharmacogovernance: Advancing Pharmacovigilance and Patient Safety 25. Pharmaceutical Policy: Synthesis, Themes and Future Directions